These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 29629740)

  • 21. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of transdermal estradiol in combination with oral norethisterone on lipoproteins, coagulation, and endothelial markers in postmenopausal women with type 2 diabetes: a randomized, placebo-controlled study.
    Perera M; Sattar N; Petrie JR; Hillier C; Small M; Connell JM; Lowe GD; Lumsden MA
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1140-3. PubMed ID: 11238498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes of nitric oxide and endothelin plasma levels and effects of hormone replacement therapy in postmenopausal women].
    Lai A; Zhang J; Ding L
    Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):222-4. PubMed ID: 11776165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of hormone therapy on the enteroinsular axis.
    Sztefko K; Rogatko I; Milewicz T; Józef K; Tomasik PJ; Szafran Z
    Menopause; 2005; 12(5):630-638. PubMed ID: 16145319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of the central effects of different progestins used in hormone replacement therapy.
    Cagnacci A; Arangino S; Baldassari F; Alessandrini C; Landi S; Volpe A
    Maturitas; 2004 Aug; 48(4):456-62. PubMed ID: 15283939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beneficial effects of postmenopausal hormone replacement therapy with transdermal estradiol on sensitivity to activated protein C.
    De Mitrio V; Marino R; Cicinelli E; Galantino P; Di Bari L; Giannoccaro F; De Pergola G; Lapecorella M; Schonauer S; Schiraldi O
    Blood Coagul Fibrinolysis; 2000 Mar; 11(2):175-82. PubMed ID: 10759011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
    Bellantoni MF; Harman SM; Cho DE; Blackman MR
    J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced expression of endothelial cell markers after long-term transdermal hormone replacement therapy in women with coronary artery disease.
    Seljeflot I; Arnesen H; Hofstad AE; Os I
    Thromb Haemost; 2000 Jun; 83(6):944-8. PubMed ID: 10896253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of estrogen replacement therapy on cardiac function in postmenopausal women with and without flushes.
    Beljic T; Babic D; Marinkovic J; Prelevic GM
    Gynecol Endocrinol; 1999 Apr; 13(2):104-12. PubMed ID: 10399055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
    Fioretti P; Gambacciani M; Spinetti A; Cagnacci A; Paoletti AM; Felipetto R; Melis GB
    Ann N Y Acad Sci; 1991; 622():302-6. PubMed ID: 1829595
    [No Abstract]   [Full Text] [Related]  

  • 31. Hormone replacement therapy does not affect plasma homocysteine in postmenopausal women with coronary artery disease. Free tissue factor pathway inhibitor antigen, a circulating anticoagulant, is related to plasma homocysteine.
    Os I; Os A; Sandset PM; Bølling S; Seljeflot I; Djurovic S; Westheim A
    Cardiology; 2002; 98(1-2):6-12. PubMed ID: 12373040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia.
    Rosano GM; Gebara O; Sheiban I; Silvestri A; Wajngarten M; Vitale C; Aldrighi JM; Ramires AF; Fini M; Mercuro G
    Int J Cardiol; 2007 Mar; 116(1):34-9. PubMed ID: 16814412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of transdermal estrogen therapy on some vasoactive humoral factors and 24-h ambulatory blood pressure in normotensive postmenopausal women.
    Zacharieva S; Atanassova I; Kirilov G; Kalinov K; Shigarminova R; Nachev E; Aslanova N
    Climacteric; 2002 Sep; 5(3):293-9. PubMed ID: 12419088
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women.
    Fak AS; Erenus M; Tezcan H; Caymaz O; Atagündüz P; Oktay S; Oktay A
    Eur Heart J; 2000 Feb; 21(3):190-7. PubMed ID: 10639300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels.
    Chiantera V; Sarti CD; Fornaro F; Farzati A; De Franciscis P; Sepe E; Borrelli AL; Colacurci N
    Menopause; 2003; 10(4):286-91. PubMed ID: 12851511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transdermal estradiol reduces F2alpha-isoprostane levels in postmenopausal women.
    Hermenegildo C; Oviedo PJ; Laguna A; García-Pérez MA; Tarín JJ; Cano A
    Menopause; 2008; 15(4 Pt 1):714-7. PubMed ID: 18340278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclic hormonal replacement therapy after the menopause: transdermal versus oral treatment.
    Cortellaro M; Nencioni T; Boschetti C; Ortolani S; Buzzi F; Francucci B; Caraceni MP; Abelli P; Polvani F; Zanussi C
    Eur J Clin Pharmacol; 1991; 41(6):555-9. PubMed ID: 1667755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women.
    Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Kurabayashi M
    Atherosclerosis; 2006 Dec; 189(2):436-42. PubMed ID: 16469323
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women.
    Kaplan PB; Gücer F; Sayin NC; Yüce MA; Yardim T
    J Reprod Med; 2002 Aug; 47(8):651-5. PubMed ID: 12216432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma leptin in postmenopausal women with coronary artery disease: effect of transdermal 17beta-estradiol and intermittent medroxyprogesterone acetate.
    Os I; Os A; Abdelnoor M; Larsen A; Birkeland K; Westheim A
    Climacteric; 2003 Sep; 6(3):204-10. PubMed ID: 14567768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.